In August 2017, Mallinckrodt acquired InfaCare to advance its proprietary therapy for treatment of newborns at risk for developing hyperbilirubinemia (severe jaundice).
| Headquarters | Plymouth Meeting, PA |
| Website | www.infacare.com​ |
| Pipeline | Phase 2B for infantile hyperbilirubinemia |